Stock PRFX PAINREFORM LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News PainReform Ltd.

Equities

PRFX

IL0011651580

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
0.46 USD +0.24% Intraday chart for PainReform Ltd. -4.17% -83.27%
Jun. 26 PainReform Ltd. Completes Enrollment in the Second Part of Its Phase 3 Bunionectomy Trial for Prf-110 CI
Jun. 18 Certain Warrants of PainReform Ltd. are subject to a Lock-Up Agreement Ending on 18-JUN-2024. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110
AQ
PainReform Ltd. Completes Enrollment in the Second Part of Its Phase 3 Bunionectomy Trial for Prf-110
CI
Certain Warrants of PainReform Ltd. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.
CI
Certain Ordinary Shares of PainReform Ltd. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.
CI
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
AQ
PAINREFORM : CONDENSED FINANCIAL STATEMENTS - Form 6-K
PU
PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
PainReform Provides Business Update for the First Quarter of 2024
AQ
PainReform : CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com
PU
PainReform Announces Closing of $4 Million Public Offering
AQ
PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell
MT
PainReform Announces Pricing of $4 Million Public Offering
AQ
PainReform : CEO IlanHadar Interviewed on “The Big Biz Show”
PU
Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110
CI
PainReform : Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
PU
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
AQ
PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
CI
PainReform : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS - Form 6-K
PU
PainReform : Investors Presentation – March 2024
PU
PainReform Provides Year-End Business Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRFX Stock
  4. News PainReform Ltd.